Skip to main content
Clinical Trials/NCT01768078
NCT01768078
Completed
Phase 3

Interest of Intravitreal Corticotherapy as the First-line Treatment for Post-operative Endophthalmitis.

Centre Hospitalier Universitaire Dijon6 sites in 1 country112 target enrollmentSeptember 2008

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Post-operative Endophthalmitis
Sponsor
Centre Hospitalier Universitaire Dijon
Enrollment
112
Locations
6
Primary Endpoint
Measure the evolution of visual acuity
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

One useful effect of early intravitreal corticotherapy is to diminish inflammatory complications after endophthalmitis, which may cause, at least in part, serious complications (retinal detachment, macular edema) which are, more than the infection, causes of the complications seen after acute endophthalmitis.

Registry
clinicaltrials.gov
Start Date
September 2008
End Date
October 2014
Last Updated
7 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • All patients male or female with no age limit
  • Hospitalized for the diagnosis and treatment of acute endophthalmitis following cataract surgery
  • Who had given their consent after being informed about intravitreal corticotherapy

Exclusion Criteria

  • Patients who refused or were unable to give their consent
  • Prior intravitreal corticotherapy

Outcomes

Primary Outcomes

Measure the evolution of visual acuity

Time Frame: up to12 months

Study Sites (6)

Loading locations...

Similar Trials